Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing repeatedly and the disease becoming increasingly resistant to therapy over time.
But a new drug made by Seattle-based Gilead Sciences Inc. appears to offer hope for fighting the disease, according to a study published online today in the New England Journal of Medicine in advance of its March 13 print issue.
The phase 2 study involved 125 patients aged 33 to 87 with indolent non-Hodgkin lymphoma (iNHL) who had not responded to conventional treatments or had relapsed within six months of therapy. The patients, who were from the Seattle area, around the United States and Europe, were given a twice-daily dose of idelalisib, a highly selective oral drug that inhibits phosphoinositide 3-kinase (PI3K) delta. P13K deltas are a family of enzymes seen in many types of B-cell malignancies.
Following treatment with idelalisib, tumor size shrunk by at least half in 57 percent of the patients and 6 percent had no measurable evidence of cancer.
"These are patients who had exhausted current standard therapies," said Ajay Gopal, M.D., a member of Fred Hutchinson Cancer Research Center's Clinical Research Division and the study's lead and corresponding author. "In terms of effective therapy available, there really wasn't much left."
Indolent non-Hodgkin lymphomas comprise about one-third of all cases of NHL. About 20,000 people in the United States were diagnosed with iNHL in 2012 and approximately 7,000 died of the disease. The standard treatment for iNHL is a combination of rituximab, a drug that targets the protein CD20 found on B cells, and chemotherapy.
While conventional treatment can be initially effective, iNHLs relapse over time and can lead to life-threatening complications such as infections and marrow failure. And unlike the toxic effects of chemotherapy, the most common side effects among patients in the trial were diarrhea and colitis, which occurred in a minority of participants and could usually be managed with dosage adjustments.
The NEJM paper, which was funded by Gilead Sciences and involved co-authors from 17 institutions in the U.S. and Europe, is the first publication of clinical data on idelalisib. The U.S. Food and Drug Administration (FDA) accepted the drug for review in early January and also gave it a Breakthrough Therapy designation for treatment of relapsed chronic lymphocytic leukemia (CLL) based on the results of another clinical trial.
Gopal, who helped write the protocol for the trial and treated many of the patients involved, said while it doesn't appear that the drug is curative, it holds tremendous promise for helping to control the disease for long periods of time.
"I think there's going to be a lot of interest in it," he said.
Gopal, also an associate professor at the University of Washington School of Medicine and the director of clinical research for hematology at Seattle Cancer Care Alliance, said depending on the FDA review, idelalisib could be approved for clinical use later this year. Such drugs, he said, represent a highly targeted and less harmful approach to treating cancer.
"Chemotherapy is a very blunt instrument," he said. "This is much more specific."
Deborah Bach | EurekAlert!
Zinc Deficiency Linked to Activation of Hedgehog Signaling Pathway
20.04.2015 | Rensselaer Polytechnic Institute (RPI)
UV light robot to clean hospital rooms could help stop spread of 'superbugs'
15.04.2015 | Texas A&M University
Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) and the University of Konstanz are working on storing and processing information on the level of single molecules to create the smallest possible components that will combine autonomously to form a circuit. As recently reported in the academic journal Advanced Science, the researchers can switch on the current flow through a single molecule for the first time with the help of light.
Dr. Artur Erbe, physicist at the HZDR, is convinced that in the future molecular electronics will open the door for novel and increasingly smaller – while also...
Cells of the vascular system of vertebrates can fuse with themselves. This process, which occurs when a blood vessel is no longer necessary and pruned, has now been described on the cellular level by Prof. Markus Affolter from the Biozentrum of the University of Basel. The findings of this study have been published in the journal “PLoS Biology”.
The vascular system is the supply network of the human organism and delivers oxygen and nutrients to the last corners of the body. So far, research on the...
Astronomers from Chalmers University of Technology have used the giant telescope Alma to reveal an extremely powerful magnetic field very close to a supermassive black hole in a distant galaxy
Astronomers from Chalmers University of Technology have used the giant telescope Alma to reveal an extremely powerful magnetic field very close to a...
A team of physicists from MPQ, Caltech, and ICFO proposes the combination of nano-photonics with ultracold atoms for simulating quantum many-body systems and creating new states of matter.
Ultracold atoms in the so-called optical lattices, that are generated by crosswise superposition of laser beams, have been proven to be one of the most...
According to new research out of the Texas A&M Health Science Center College of Medicine, that is indeed the case. Chetan Jinadatha, M.D., M.P.H., assistant...
13.04.2015 | Event News
25.03.2015 | Event News
19.03.2015 | Event News
20.04.2015 | Physics and Astronomy
20.04.2015 | Architecture and Construction
20.04.2015 | Physics and Astronomy